Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

January 18, 2024

https://www.globenewswire.com/news-release/2024/01/18/2811956/33333/en/Coherus-Presents-Positive-Phase-2-Clinical-Data-on-Casdozokitug-a-First-in-Class-IL-27-Targeted-Antibody-at-the-2024-ASCO-GI-Cancers-Symposium.html

– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses –

– Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that may be associated with IL-27 pathway biomarkers –

Read more at globenewswire.com

Related news for (CHRS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.